Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease

Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma

“…6 Although complications related to SCD are described with G-CSF use, Shah et al report on 62 SCD patients who did not develop complications with G-CSF post-allograft; however, risk of VOC in this setting would be expected to be low. 14 Given conflicting literature we propose avoiding G-CSF during ASCT. This will delay counting recovery from expected neutrophil engraftment on day+11 (using G-CSF from day+6 in our centre) to between day+17 and 21 in our two reported patients.…”

Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease

“…Strategies include pentosta phosphamide (NCT# 03077542), dexamethasone and fludarabine [43], and and azathioprine [94]. Granulocyte stimulants like gCSF are also being em in the post-HCT to enhance neutrophil recovery [95]. Finally, new condition that avoid genotoxicity altogether represent the next wave of HCT develo CD117 and anti-CD45 antibodies have been conjugated with immunotoxins in experimental models to effectively condition mice without concomita [96,97].…”

“…Strategies include pentosta phosphamide (NCT# 03077542), dexamethasone and fludarabine [43], and and azathioprine [94]. Granulocyte stimulants like gCSF are also being em in the post-HCT to enhance neutrophil recovery [95]. Finally, new condition that avoid genotoxicity altogether represent the next wave of HCT develo CD117 and anti-CD45 antibodies have been conjugated with immunotoxins…”